Back to Search
Start Over
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma
- Source :
- Oncotarget
- Publication Year :
- 2017
-
Abstract
- A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients.
- Subjects :
- Oncology
medicine.medical_specialty
Hodgkin’s lymphoma
Context (language use)
Neutropenia
stem cell transplantation
NO
Efficacy
03 medical and health sciences
0302 clinical medicine
brentuximab vedotin
real life
Internal medicine
medicine
long-term response
Progression-free survival
Brentuximab vedotin
Hodgkin's lymphoma
business.industry
Retrospective cohort study
medicine.disease
Clinical trial
Long-term response
Real life
Stem cell transplantation
030220 oncology & carcinogenesis
Clinical Research Paper
business
030215 immunology
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Oncotarget
- Accession number :
- edsair.doi.dedup.....94457167f00c920b149713c4f8512072